Abliva AB (publ) is a pharmaceutical firm focused on developing novel treatments for primary mitochondrial disorders. Its product pipeline features KL1333, currently in Phase 2/3 clinical trials for the long-term management of these conditions. Another compound, NV354, is undergoing preparations for clinical studies, specifically targeting primary mitochondrial diseases linked to Complex I deficiency.